Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001213900-25-066359
Filing Date
2025-07-22
Accepted
2025-07-22 08:57:55
Documents
6

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 17316
2 JOINT FILING AGREEMENT, DATED JULY 22, 2025, AMONG THE REPORTING PERSONS ea024982001ex99-1_lakeshore.htm EX-99.1 5142
3 SHARE AND WARRANT PURCHASE AGREEMENT, DATED JULY 8, 2025, BY AND BETWEEN THE ISS ea024982001ex99-2_lakeshore.htm EX-99.2 171801
4 GRAPHIC ex99-2_001.jpg GRAPHIC 12160
5 GRAPHIC ex99-2_002.jpg GRAPHIC 6053
6 GRAPHIC ex99-2_003.jpg GRAPHIC 5774
  Complete submission text file 0001213900-25-066359.txt   229707
Mailing Address BUILDING NO. 2, 38 YONGDA ROAD DAXING BIOMEDICAL INDUSTRY PARK DAXING DISTRICT, BEIJING F4 102629
Business Address BUILDING NO. 2, 38 YONGDA ROAD DAXING BIOMEDICAL INDUSTRY PARK DAXING DISTRICT, BEIJING F4 102629 17327133678
LakeShore Biopharma Co., Ltd. (Subject) CIK: 0001946399 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 0331
Type: SCHEDULE 13D | Act: 34 | File No.: 005-94412 | Film No.: 251138790
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 3877 EL CAMINO REAL, STE 201 PALO ALTO CA 94306
Business Address 3877 EL CAMINO REAL, STE 201 PALO ALTO CA 94306 86 13335711066
Crystal Peak Investment Inc. (Filed by) CIK: 0002078050 (see all company filings)

EIN.: 000000000 | State of Incorp.: D8 | Fiscal Year End: 0331
Type: SCHEDULE 13D